Japan High-Throughput Screening (HTS) Market (2026-2031)
The Japan High-Throughput Screening (HTS) Market was valued at $671.8 Million in 2026 and projected to reach to $993.7 Million by 2031, representing a compound annual growth rate of 13.9%. Japan's High-Throughput Screening market is positioned for accelerated growth through 2031, supported by robust pharmaceutical R&D spending and increasing adoption of automation technologies.
Japan High-Throughput Screening (HTS) Market Trends and Insights
- India's HTS sector is benefiting from accelerated pharmaceutical and biotechnology research investments, coupled with rising adoption of automation in drug discovery pipelines across Indian research institutions and contract research organizations.
- India's competitive cost advantage and growing scientific talent pool are positioning the country as a key HTS hub within Asia Pacific. The 13.9% compound annual growth rate reflects India's strengthening position in global drug development outsourcing and domestic innovation initiatives.
- India's pharmaceutical companies are increasingly integrating HTS technologies to enhance screening efficiency and reduce time-to-market for novel therapeutics.
- By 2031, India's HTS market expansion will be underpinned by government support for biotech infrastructure, rising venture capital inflows into Indian life sciences startups, and expanding collaborations between Indian research entities and multinational pharmaceutical firms seeking cost-effective screening solutions..
Key Market Statistics
- CAGR (2026-2031) 13.9% CAGR
- Market Size, 2026 ~USD 671.8 Million
- Forecast, 2031 ~USD 993.7 Million
- Country Japan
Japan High-Throughput Screening (HTS) Market Overview
Strong Market Growth :
Japan's HTS market is expanding at a CAGR of 13.9%, significantly outpacing the global average of 10.7%, driven by increased R&D investments in pharmaceutical and biotechnology sectors.
Advanced Automation Adoption :
Japanese pharmaceutical companies and research institutions are rapidly integrating automated HTS platforms into drug discovery workflows, enhancing screening efficiency and reducing time-to-market.
Strategic Government Support :
Japan's government initiatives promoting life sciences innovation and precision medicine are catalyzing HTS technology adoption across academic and commercial research facilities.
Market Valuation Trajectory :
The market is valued at USD 671.8 million in 2026 and is projected to grow to USD 993.7 million by 2031, representing substantial investment opportunities in the Japanese HTS ecosystem.
Japan High-Throughput Screening (HTS) Market Dynamics
- Japanese biotech firms and contract research organizations are investing heavily in HTS infrastructure to enhance drug discovery capabilities and maintain competitive advantage in global markets.
- The convergence of aging population demographics, rising healthcare demands, and government backing for life sciences innovation creates a favorable environment for HTS market expansion. Key drivers include Japan's established pharmaceutical manufacturing base, growing collaboration between academia and industry, and integration of artificial intelligence with HTS platforms.
- Investment in next-generation screening technologies and expansion of CRO capabilities will further propel market growth.
- By 2031, Japan is expected to emerge as a significant HTS hub in Asia-Pacific, attracting both domestic and international pharmaceutical companies seeking advanced screening solutions..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- India's HTS market is valued at USD 671.8 million in 2026, expanding at a 13.9% CAGR through 2031.
- India's cost-competitive advantage and skilled workforce are driving adoption of HTS technologies among domestic and international pharmaceutical companies.
- India's government initiatives and biotech infrastructure investments are accelerating HTS market growth and positioning India as a regional innovation leader.
- India's contract research organizations and pharmaceutical firms are increasingly automating drug discovery processes, fueling demand for advanced HTS platforms.
High-Throughput Screening (HTS) Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | LIQUID HANDLING SYSTEMS (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.7% from 2026 to 2031 |
| Largest Segment | NORTH AMERICA (Type) |
| Market Size Base Year (Billions) | ~USD 27.61 (2026) |
| Revenue Forecast (Billions) | ~USD 45.9 (2031) |
| Segments Covered | Type, Application, Technology |
Japan High-Throughput Screening (HTS) Market Report Segmentation
3 segment dimensions are covered across the global market.
By Type
- 2D Cell Cultures
- 3D Cell Cultures
- Alginate/Agarose
- Animal-Derived Hydrogels
- Collagen
- Detection Systems
- Hydrogels
- Imaging Instruments
- Inert Matrix/Solid Scaffolds
- Laboratory Consumables
- Liquid Handling Systems
- Matrigel
- Micropatterned Surfaces
- Other Instruments
- Perfusion Cell Cultures
- Reagents & Assay Kits
- Reporter-Based Assays
- Scaffold-Based Technology
- Scaffold-Free Technology
- Synthetic Hydrogels
By Application
- Biochemical Screening
- Drug Discovery
- Life Science Research
- Other Applications
By Technology
- Cell-Based Assays
- Lab-On-A-Chip
- Label-Free Technology
Target Audience
- Pharmaceutical Companies : Japanese and international pharma firms need Japan-specific HTS market data to optimize drug discovery investments, evaluate CRO partnerships, and benchmark R&D spending against market trends.
- Biotechnology Firms : Biotech companies require detailed Japan market insights to assess screening technology adoption rates, identify collaboration opportunities with local institutions, and plan market entry strategies.
- Contract Research Organizations : CROs operating in Japan need market sizing and growth forecasts to justify capacity expansion, invest in advanced HTS infrastructure, and develop service offerings aligned with client demand.
- Technology & Equipment Vendors : HTS platform and instrumentation providers require Japan-specific market data to identify customer segments, forecast demand, and develop localized sales and support strategies.
- Investment & Consulting Firms : Investors and consultants need comprehensive Japan HTS market analysis to evaluate investment opportunities, assess portfolio companies, and provide strategic guidance to life sciences clients.
Key Companies in the Japan High-Throughput Screening (HTS) Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOCARTIS SA | Belgium | Private Company | Oncology assay consumables,Instrument systems and service,Other legacy and residual activities, |
| QIAGEN NV | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, viral load),PCR and enzyme solutions (qPCR, dPCR, RT-PCR, configured enzymes), |
| CODEXIS, INC. | United States | Public Company | CodeEvolver platform-enabled enzyme sales and services,ECO Synthesis platform for RNAi and nucleic acid manufacturing,Licensing and royalties from technology partnerships, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing, single-use, filtration, aseptic fill-finish),Life Sciences (analytical instruments, genomics, lab automation),Diagnostics (clinical instruments, consumables, software, services), |
| MERCK KGAA | Germany | Public Company | Life Science,Healthcare,Electronics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and assays (BioLegend, Dharmacon, Alpha platforms),Instruments and imaging systems, |
| TECAN GROUP LTD. | Switzerland | Public Company | Liquid handling and automation platforms (incl. Tecan Labwerx),Microplate readers, washers, and detection instruments,Consumables, sequencing reagents, immunoassays, and antibodies, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, kits, and quality controls,Life Science instruments and reagents,Informatics and software, |
| CORNING INCORPORATED | United States | Public Company | Optical communications (fiber, cable, hardware, connectivity),Display glass substrates (LCD and OLED),Specialty materials and mobile consumer electronics glass, |
| METTLER-TOLEDO INTERNATIONAL INC. | Switzerland | Public Company | Laboratory instruments and LabX software,Industrial instruments and product inspection,Retail weighing and fresh-goods solutions, |
| LONZA GROUP | Switzerland | Public Company | Integrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| WATERS CORPORATION | United States | Public Company | Liquid Chromatography Systems and Columns,Mass Spectrometry Systems,TA Instruments (Thermal, Rheometry, Calorimetry), |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, filtration, chromatography, fluid management),Lab products and services (weighing, pipettes, filtration, microbiological testing),Advanced analytical and cell analysis systems (BLI, SPR, cytometry, live-cell imaging), |
| EPPENDORF SE | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
| PORVAIR PLC | United Kingdom | Public Company | Aerospace & Industrial Filtration,Laboratory Instruments and Consumables,Metal Melt Quality (Porous Ceramic Filters), |
BIOCARTIS SA
BIOCARTIS SA is a Belgian private company established in 2014 with 500 employees. The company focuses on molecular diagnostics and personalized medicine solutions.
QIAGEN NV
QIAGEN NV is a Dutch public company founded in 1984 with 5,500 employees. The company is a leading provider of molecular diagnostics, sample preparation, and life sciences research tools.
CODEXIS, INC.
CODEXIS, INC. is a United States public company founded in 2002 with 146 employees. The company develops enzyme engineering and biocatalysis solutions for pharmaceutical and industrial applications.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States public company founded in 1956 with 125,000 employees. The company is a global leader in serving science with a broad portfolio of laboratory equipment, reagents, and services.
DANAHER CORPORATION
DANAHER CORPORATION is a United States public company founded in 1969 with 59,000 employees. The company operates a diversified conglomerate with significant presence in life sciences, diagnostics, and environmental solutions.
MERCK KGAA
MERCK KGAA is a German public company founded in 1668 with 59,077 employees. The company is a global science and technology leader operating in pharmaceuticals, life sciences, and performance materials.
AGILENT TECHNOLOGIES, INC.
AGILENT TECHNOLOGIES, INC. is a United States public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences, diagnostics, and applied chemical markets.
REVVITY, INC.
REVVITY, INC. is a United States public company founded in 1937 with 11,000 employees. The company develops and manufactures analytical instruments and software for life sciences research and diagnostics.
TECAN GROUP LTD.
TECAN GROUP LTD. is a Swiss public company founded in 1980 with 3,166 employees. The company specializes in laboratory automation and detection solutions for life sciences and diagnostics applications.
BIO-RAD LABORATORIES, INC.
BIO-RAD LABORATORIES, INC. is a United States public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research products and clinical diagnostics solutions.
CORNING INCORPORATED
CORNING INCORPORATED is a United States public company founded in 1851 with 67,200 employees. The company is a diversified technology leader with significant operations in life sciences, laboratory products, and specialty materials.
METTLER-TOLEDO INTERNATIONAL INC.
METTLER-TOLEDO INTERNATIONAL INC. is a Swiss public company founded in 1991 with 16,600 employees. The company manufactures precision instruments and services for laboratory, industrial, and retail applications.
LONZA GROUP
LONZA GROUP is a Swiss public company founded in 1897 with 20,000 employees. The company is a leading supplier of products and services for the pharmaceutical, biotech, and specialty chemical industries.
WATERS CORPORATION
WATERS CORPORATION is a United States public company founded in 1958 with 7,900 employees. The company develops and manufactures analytical instruments and software for laboratory and life sciences applications.
SARTORIUS AG
SARTORIUS AG is a German public company founded in 1870 with 14,242 employees. The company provides laboratory and process technologies for pharmaceutical, biotech, and food industries.
EPPENDORF SE
EPPENDORF SE is a German private company founded in 1945 with 4,358 employees. The company manufactures laboratory equipment and consumables for life sciences research and diagnostics.
PORVAIR PLC
PORVAIR PLC is a United Kingdom public company founded in 1982 with 992 employees. The company manufactures advanced filtration and separation products for life sciences and industrial applications.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise valuation data for Japan's HTS market (USD 671.8M in 2026, USD 993.7M in 2031) with detailed CAGR analysis to support investment decisions and business planning.
- Competitive Landscape Intelligence : Understand Japan-specific competitive dynamics, key players, and market positioning strategies to identify partnership opportunities and competitive advantages in the Japanese HTS sector.
- Regulatory & Technology Insights : Access Japan-specific regulatory frameworks, technology adoption trends, and automation standards to ensure compliance and optimize HTS platform deployment in the Japanese market.
- Strategic Market Entry Planning : Leverage Japan-focused market segmentation, customer profiles, and growth drivers to develop targeted go-to-market strategies and identify high-potential customer segments.
- Investment & Expansion Roadmap : Utilize comprehensive Japan market forecasts and trend analysis to guide capital allocation, facility expansion, and technology investment decisions through 2031.
Frequently asked questions
What is the current size of India's High-Throughput Screening market?
India's HTS market was valued at USD 671.8 million in 2026 and is projected to grow to USD 993.7 million by 2031, representing a 13.9% compound annual growth rate.
What factors are driving growth in India's HTS market?
India's HTS market growth is driven by increased pharmaceutical R&D investments, rising adoption of automation in drug discovery, government biotech infrastructure support, and India's cost-competitive advantage attracting global outsourcing partnerships.
How does India's HTS market compare to global trends?
India's HTS market is growing at 13.9% CAGR, outpacing the global HTS market CAGR of 10.7%, reflecting India's accelerating role in drug discovery and development within the Asia Pacific region.
Which sectors are driving HTS adoption in India?
India's pharmaceutical companies, contract research organizations, biotechnology startups, and academic research institutions are primary drivers of HTS adoption, leveraging the technology for efficient drug screening and development.
What is the forecast for India's HTS market by 2031?
India's HTS market is forecasted to reach USD 993.7 million by 2031, driven by continued investment in biotech infrastructure, government support for life sciences innovation, and expanding international collaborations in drug discovery.
RESEARCH METHODOLOGY
This research study relied heavily on secondary sources, directories, and databases to identify and collect valuable information for analyzing the global high-throughput screening (HTS) market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the high-throughput screening (HTS) market. The secondary sources used for this study include World Health Organization (WHO), American Society for Clinical Laboratory Science (ASCLS), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), American Association for Clinical Chemistry (AACC), National Center for Advancing Translational Sciences (NCATS), American Society for Pharmacology and Experimental Therapeutics (ASPET), National Health Service (NHS), Pharmaceuticals and Medical Devices Agency (PMDA), European Medicines Agency (EMA), Society for Laboratory Automation and Screening (SLAS), European Bioinformatics Institute, and Center for Translational Research, among others. Corporate filings include annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data were collected and analyzed to determine the overall size of the global high-throughput screening (HTS) market, which was subsequently validated through primary research. These sources were also used to obtain key information on major players, market classification, and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess the market's future prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were employed to estimate and validate the overall size of the high-throughput screening (HTS) market. These methods were also widely used to determine the size of various market segments. The research methodology used to estimate the market size includes the following:
High-Throughput Screening (HTS) Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size, the total market was divided into segments and subsegments. Data triangulation and market breakdown techniques were used where applicable to finalize the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both demand and supply sides.
Market Definition
High-throughput screening (HTS) is a drug discovery process that involves automated testing of large quantities of chemical or biological compounds against specific biological targets using various binding assays.
The HTS market comprises products (instruments, reagents & consumables, software), and services used to perform automated, parallel screening of large compound or biological libraries against defined biological targets or assays to identify active entities (hits). The high-throughput screening (HTS) market comprises workflow stages from assay development and compound library management to automated large-scale screening and hit identification, culminating in validated screening hits.
Key Stakeholders
- Contract research organizations
- Pharmaceutical & biopharmaceutical companies
- Academic & research institutes
- High-throughput screening instrument & reagent manufacturers
- High-content screening database, service, and software providers
- Venture capitalists & investors
- Market research & consulting firms
- Government associations
- Medical institutions & universities
Report Objectives
- To define, describe, and forecast the high-throughput screening (HTS) market by offering, products by type, products by technology, products by workflow, products by end user, services by type, services by end user, application, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall high-throughput screening (HTS) market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players and analyze their market shares and core competencies2
- To track and analyze competitive developments, such as product & service launches, agreements, partnerships, acquisitions, and research & development activities
- To analyze and provide funding & investment activities, brand/product/service comparative analysis, and vendor valuation & financial metrics of the high-throughput screening (HTS) market
Customization Options
Based on the given market data, MarketsandMarkets offers customization to meet the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product/Service Matrix gives a detailed comparison of the product/service portfolios of the top five companies.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Geographical Analysis
- Further breakdown of the Rest of Europe high-throughput screening (HTS) market, by country
- Further breakdown of the Rest of Asia Pacific high-throughput screening (HTS) market, by country
- Further breakdown of the Rest of Latin America high-throughput screening (HTS) market, by country
Get the Full High-Throughput Screening (HTS) Market Report
Full forecast, segment splits, and company analysis for all High-Throughput Screening (HTS) Market.
- Canada High-Throughput Screening (HTS) Market
- US High-Throughput Screening (HTS) Market
- Germany High-Throughput Screening (HTS) Market
- UK High-Throughput Screening (HTS) Market
- France High-Throughput Screening (HTS) Market
- Italy High-Throughput Screening (HTS) Market
- Spain High-Throughput Screening (HTS) Market
- China High-Throughput Screening (HTS) Market
- India High-Throughput Screening (HTS) Market
- Australia High-Throughput Screening (HTS) Market
- South Korea High-Throughput Screening (HTS) Market
- Brazil High-Throughput Screening (HTS) Market
- Mexico High-Throughput Screening (HTS) Market
- Saudi Arabia High-Throughput Screening (HTS) Market
- UAE High-Throughput Screening (HTS) Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report